新月直播app下载

Phishing warning 01-May-2024
We are aware of phishing emails targeting speakers of events whose names appear on our events pages. If you are unsure if an email regarding event registration or accommodation has come from us please contact us and do not provide any credit card details or personal information

RSC Desktop Seminar Series with RSC Medicinal Chemistry & RSC-BMCS

12 January 2022 09:00-10:30, Online


Introduction
Welcome to the latest RSC Desktop Seminars hosted by RSC Medicinal Chemistry and the RSC-BMCS (Biological & Medicinal Chemistry Sector). Each 80-minute seminar in this free series will feature talks from an RSC Medicinal Chemistry Editorial Board member and a BMCS prize winner/RSC Medicinal Chemistry author.

Join RSC Medicinal Chemistry Associate Editor Professor Yonghui Zhang (Tsinghua University, China) and Dr. Nichola Davies (AstraZeneca, UK) in our third session in the Desktop Seminar Series with RSC Medicinal Chemistry and the RSC-BMCS. Introductions will be given by RSC Medicinal Chemistry Executive Editor, Dr. Katie Lim, and Chairman of the RSC-BMCS, Dr Andrew Williams.

This 80-minute seminar will allow researchers of all professional levels to connect, share ideas, and ask questions. Be sure to register for the free seminar series today!

Speakers

Dr Nichola Davies
"Experimental Structure Property Relationships in the bRo5 space"

Professor Yonghui Zhang
鈥淒evelopment of New Immunotherapies by Targeting Isoprenoid Metabolism鈥

Programme

09: 00 GMT (5:00 PM CST) 鈥 Welcome & introduction
 
09:05 GMT (5:05 PM CST) 鈥 "Experimental Structure Property Relationships in the bRo5 space", Nichola Davies (AstraZeneca)
 
09:30 GMT (5:30 PM CST) 鈥 Q&A with Dr Nichola Davies
 
09:40 GMT (5:40 PM CST) 鈥 鈥淒evelopment of New Immunotherapies by Targeting Isoprenoid Metabolism鈥, Yonghui Zhang (Tsinghua University)
 
10:05 GMT (6:05 PM CST) 鈥 Q&A with Professor Yonghui Zhang
 
10:15 GMT (6:15 PM CST) 鈥 Closing remarks
 
Speakers
Dr Nichola Davies, AstraZeneca, United Kingdom

Team Leader, Structural Chemistry, Oncology R&D, Chemistry, AstraZeneca, Cambridge, UK
Nichola Davies completed her PhD studies in physical organic chemistry at the University of Cambridge, utilising 新月直播app下载 spectroscopy to investigate positively cooperative binding and the tightening of non-covalent bonds. Nichola then joined Pfizer (Sandwich, UK) as an 新月直播app下载 spectroscopist supporting the medicinal chemistry department and implemented new techniques for structure elucidation and the application of novel 新月直播app下载 methodologies to support medicinal chemistry design strategies.

Having gained further experience in a wider range of analytical techniques, in 2014 she joined AstraZeneca (Cambridge, UK), as an 新月直播app下载 expert within the Oncology Chemistry R&D Unit. Currently a team leader for the structural chemistry unit, Nichola is delivering analytical techniques to support small molecule structural characterisation, purity and stability assessment, in addition to 新月直播app下载 free ligand conformational analysis and in-cell MS concentration assays.


Professor Yonghui Zhang, Tsinghua University, China

Yonghui Zhang received his Ph.D in Chemistry in 2002 from Shanghai Institute of Organic Chemistry, Chinese Academy of 新月直播app下载s and pursued his postdoctoral training at the University of Illinois at Urbana-Champaign in the United States. Dr. Zhang is now a Professor at the School of Pharmaceutical 新月直播app下载s of Tsinghua University, a leader of higher education and academic research in China. Dr. Zhang has published over 60 papers in the field of medicinal chemistry, organic chemistry, chemical biology and immunology.

He has pioneered in discovering and characterizing the relationship between lipid metabolism and immune regulation. By using a multidisciplinary approach involving structural biology, molecular immunology, cell and mice models, and medicinal chemistry, he demonstrated that the mevalonate pathway is a druggable target for vaccine adjuvants and developed lipophilic bisphosphonates and statins as Th-1 vaccine adjuvants. Currently, his lab is developing and applying innovative chemical approaches to a variety of immuno-modulatory process, with a focus on vaccination, allogeneic immune cell therapy and new anti-infection strategy.



Venue
GoToWebinar

GoToWebinar, Online,

Organised by
Contact information
Search
 
 
Showing all upcoming events
Start Date
End Date
Location
Subject area
Event type

Advertisement
Spotlight


E-mail Enquiry
*
*
*
*